KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation.
作者信息
Jackson William F
出版信息
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1073-4. doi: 10.1161/ATVBAHA.110.206565.
Abstract
摘要
相似文献
1
KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation.
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1073-4. doi: 10.1161/ATVBAHA.110.206565.
2
Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1203-11. doi: 10.1161/ATVBAHA.110.205187. Epub 2010 Mar 18.
3
Blocking potassium channels: a new principle for treating restenosis?
Cardiovasc Res. 2011 Feb 1;89(2):255-7. doi: 10.1093/cvr/cvq388. Epub 2010 Dec 14.
4
Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers.
Cardiovasc Res. 2011 Feb 1;89(2):282-9. doi: 10.1093/cvr/cvq305. Epub 2010 Sep 29.
5
Kv1.3 blockade inhibits proliferation of vascular smooth muscle cells in vitro and intimal hyperplasia in vivo.
Transl Res. 2020 Oct;224:40-54. doi: 10.1016/j.trsl.2020.06.002. Epub 2020 Jun 6.
6
Myocardial Blood Flow Control by Oxygen Sensing Vascular Kvβ Proteins.
Circ Res. 2021 Mar 19;128(6):738-751. doi: 10.1161/CIRCRESAHA.120.317715. Epub 2021 Jan 27.
7
Kv1.3 channels modulate human vascular smooth muscle cells proliferation independently of mTOR signaling pathway.
Pflugers Arch. 2015 Aug;467(8):1711-22. doi: 10.1007/s00424-014-1607-y. Epub 2014 Sep 12.
8
K+ channels expression in hypertension after arterial injury, and effect of selective Kv1.3 blockade with PAP-1 on intimal hyperplasia formation.
Cardiovasc Drugs Ther. 2014 Dec;28(6):501-11. doi: 10.1007/s10557-014-6554-5.
9
Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification.
Cardiovasc Res. 2018 Mar 15;114(4):477-480. doi: 10.1093/cvr/cvy031.
10
Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation.
J Cell Physiol. 2021 Jun;236(6):4330-4347. doi: 10.1002/jcp.30170. Epub 2020 Nov 23.
引用本文的文献
1
Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade.
Nat Nanotechnol. 2024 Dec;19(12):1903-1913. doi: 10.1038/s41565-024-01758-3. Epub 2024 Aug 26.
2
Encainide, a class Ic anti-arrhythmic agent, blocks voltage-dependent potassium channels in coronary artery smooth muscle cells.
Korean J Physiol Pharmacol. 2023 Jul 1;27(4):399-406. doi: 10.4196/kjpp.2023.27.4.399.
3
Kv1.3 voltage-gated potassium channels link cellular respiration to proliferation through a non-conducting mechanism.
Cell Death Dis. 2021 Apr 7;12(4):372. doi: 10.1038/s41419-021-03627-6.
4
Myocardin and Kv1 Channels: A Paradigm Shift in Treating Vascular Smooth Muscle Cell-Related Proliferative Disease?
Arterioscler Thromb Vasc Biol. 2019 Dec;39(12):2454-2456. doi: 10.1161/ATVBAHA.119.313531. Epub 2019 Nov 26.
5
Kv1.3 channels facilitate the connection between metabolism and blood flow in the heart.
Microcirculation. 2017 May;24(4). doi: 10.1111/micc.12334.
6
The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.
PLoS One. 2013 Nov 29;8(11):e81006. doi: 10.1371/journal.pone.0081006. eCollection 2013.
本文引用的文献
1
Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1203-11. doi: 10.1161/ATVBAHA.110.205187. Epub 2010 Mar 18.
2
The functional network of ion channels in T lymphocytes.
Immunol Rev. 2009 Sep;231(1):59-87. doi: 10.1111/j.1600-065X.2009.00816.x.
3
Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.
Oncogene. 2009 Apr 16;28(15):1792-806. doi: 10.1038/onc.2009.25. Epub 2009 Mar 9.
4
The intermediate-conductance Ca2+ -activated K+ channel (KCa3.1) in vascular disease.
Cardiovasc Hematol Agents Med Chem. 2009 Jan;7(1):1-11. doi: 10.2174/187152509787047649.
5
Physiology of cell volume regulation in vertebrates.
Physiol Rev. 2009 Jan;89(1):193-277. doi: 10.1152/physrev.00037.2007.
6
T-cell costimulation and coinhibition in atherosclerosis.
Circ Res. 2008 Nov 21;103(11):1220-31. doi: 10.1161/CIRCRESAHA.108.182428.
7
Potassium channels keep mobile cells on the go.
Physiology (Bethesda). 2008 Aug;23:212-20. doi: 10.1152/physiol.00003.2008.
8
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
J Clin Invest. 2008 Sep;118(9):3025-37. doi: 10.1172/JCI30836.
9
Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1084-9. doi: 10.1161/ATVBAHA.107.155796. Epub 2008 Feb 28.
10
Cell volume regulatory ion channels in cell proliferation and cell death.
Methods Enzymol. 2007;428:209-25. doi: 10.1016/S0076-6879(07)28011-5.
Zotero 插件